Search for: "Sanofi S A"
Results 121 - 140
of 933
Sorted by Relevance
|
Sort by Date
7 Oct 2009, 9:59 pm
Sanofi originally filed suit against Sun, Sandoz, Actavis Inc., and Par Pharmaceutical Inc., among other generic manufacturers, in June 2007, accusing them of infringing Sanofi's patent covering Eloxatin ®, U.S. [read post]
14 Dec 2010, 7:06 pm
’s (“sanofi’s”) blockbuster anti-coagulant drug LOVENOX (enoxaparin sodium injection), Judge Emmet G. [read post]
27 Mar 2023, 8:50 pm
Noonan -- The Supreme Court's decision to grant certiorari in Amgen v. [read post]
26 Mar 2023, 9:07 pm
Noonan -- The Supreme Court's decision to grant certiorari in Amgen v. [read post]
14 Mar 2023, 8:58 pm
Noonan -- The Supreme Court's decision to grant certiorari in Amgen v. [read post]
6 Oct 2021, 12:59 pm
But that’s not the necessary implication of the true claim about Sanofi’s retractable needle. [read post]
20 Aug 2010, 4:47 am
Judge Gregory Sleet of the US District Court for the District of Delaware lately decided in favor of Sanofi-Aventis in Uroxatral patent lawsuit and ruled that Sanofi’s US Patent Number 4,661,491 is valid and infringed by generic alfuzosin versions from Aurobindo Pharma and Torrent Pharma Inc. [read post]
15 Mar 2016, 9:00 am
Thus, Sanofi’s failure to specifically disclose the FDA’s concerns regarding the use of a single-blind study in Lemtrada’s clinical trials was not sufficient to render Sanofi’s statements of opinion actionable. [read post]
11 Dec 2006, 12:59 am
Apotex (06-1613) December 8, 2006The Federal Circuit issued it's opinion in the Sanofi case Friday, affirming the lower court's grant of a preliminary injunction against Apotex's generic version of Plavix. [read post]
5 Feb 2023, 9:37 pm
Noonan -- Facing what is likely to be something of an uphill battle in seeking to have the Federal Circuit's decision against it in Amgen v Sanofi overturned before a not always patent-friendly Supreme Court, Amgen in late December filed its opening brief addressing the Question Presented in the granted certiorari petition: Whether enablement is governed by the statutory requirement that the specification teach those skilled in the art to "make and use" the… [read post]
11 Oct 2010, 5:48 am
Today's Lex column in the FT.com has a quickie review of some of the potential defenses available to Genzyme in its fight to stave of Sanofi - the pacman defense*, the macaroni defense**, the poison pill, scorched earth tactics, and... [read post]
30 Jul 2008, 5:37 pm
In a Feb 19, 2008 order, the district court denied Novo’s request for a preliminary injunction – finding that Sanofi has a strong non-infringement argument. [read post]
29 Apr 2021, 6:39 am
Sanofi – Biogen BMS Corning Brief (The jury’s role in determining enablement should be restored, etc.). [read post]
28 Apr 2015, 2:36 am
Eventually, Sanofi’s patent was found to be invalid, implying that a cheaper generic version of the drug could have been made available all along. [read post]
7 Feb 2014, 7:38 am
Bloomberg News reports Sanofi’s multiple sclerosis drug Lemtrada (alemtuzumab) failed to get approval from the FDA, “denting the company’s ambitions of capturing a larger share of the $20 billion market for the disease. [read post]
14 Jul 2009, 9:55 pm
In response to Sanofi's and Debiopharm's complaint, Ebewe... [read post]
6 Nov 2022, 8:53 am
Sanofi. [read post]
5 Mar 2024, 10:23 am
Sanofi Opinion. [read post]
29 Mar 2017, 5:15 am
The major impetus behind this suit was Sanofi-Aventis and Regeneron’s discovery that Amgen hired litigation counsel to assert the ‘487 patent and is also working on retaining experts. [read post]
30 Aug 2019, 6:09 am
Amgen brought suit alleging that Sanofi/Regeneron’s production of Praluent violated patents they had secured. [read post]
